Vobarilizumab

Drug Profile

Vobarilizumab

Alternative Names: ALX 0061; ANTI-IL-6R; Anti-IL-6R Nanobody

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ablynx
  • Class Antirheumatics; Proteins
  • Mechanism of Action Interleukin 6 receptor antagonists; Interleukin 6 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Rheumatoid arthritis

Highest Development Phases

  • Phase II Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 15 Dec 2016 Ablynx completes enrolment in the phase II STEADY trial for Systemic lupus erythmatosus in USA, Hungary, Russia, Spain, Ukraine, Portugal, Poland, Serbia, Philippines, Taiwan, Mexico, Czech Republic, Germany, Chile and South Korea
  • 28 Nov 2016 Vobarilizumab is available for licensing as of 23 Nov 2016 in Rheumatoid arthritis
  • 20 Oct 2016 Ablynx plans a phase III trial for Rheumatoid arthritis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top